{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:20:05Z","timestamp":1793488805742,"version":"4.5.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00198-017-4082-4","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T10:50:20Z","timestamp":1497869420000},"page":"2541-2556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":303,"title":["Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability"],"prefix":"10.1007","volume":"28","author":[{"name":"for the National Bone Health Alliance Bone Turnover Marker Project","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-6697","authenticated-orcid":false,"given":"P.","family":"Szulc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R.","family":"Hoyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. T.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"4082_CR1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391\u2013420","journal-title":"Osteoporos Int"},{"key":"4082_CR2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","volume":"8","author":"K Naylor","year":"2012","unstructured":"Naylor K, Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8:379\u2013389","journal-title":"Nat Rev Rheumatol"},{"key":"4082_CR3","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","volume":"19","author":"P Szulc","year":"2008","unstructured":"Szulc P, Delmas PD (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19:1683\u20131704","journal-title":"Osteoporos Int"},{"key":"4082_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1373\/clinchem.2011.164012","volume":"57","author":"GW Miller","year":"2011","unstructured":"Miller GW, Myers GL, Lou Gantzer M, Kahn SE, Sch\u00f6nbrunner ER, Thienpont LM, Bunk DM, Christenson RH, Eckfeldt JH, Lo SF, N\u00fcbling CM, Sturgeon CM (2011) Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 57:1108\u20131117. doi: 10.1373\/clinchem.2011.164012","journal-title":"Clin Chem"},{"key":"4082_CR5","doi-asserted-by":"crossref","unstructured":"Szulc P, Bauer DC, Eastell R (2013) Biochemical markers of bone turnover in osteoporosis. In: Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th Edition. Ed. in Chief: CJ Rosen, ASBMR and Willey-Blackwell, 297\u2013306","DOI":"10.1002\/9781118453926.ch35"},{"key":"4082_CR6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1572-0241.2006.01036.x","volume":"102","author":"H Koivisto","year":"2007","unstructured":"Koivisto H, Hietala J, Niemel\u00e4 O (2007) An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease. Am J Gastroenterol 102:773\u2013779","journal-title":"Am J Gastroenterol"},{"key":"4082_CR7","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1210\/jc.2015-2957","volume":"100","author":"P Chavassieux","year":"2015","unstructured":"Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R (2015) Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 100:4662\u20134668. doi: 10.1210\/jc.2015-2957","journal-title":"J Clin Endocrinol Metab"},{"key":"4082_CR8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/clinchem\/42.6.947","volume":"42","author":"J Melkko","year":"1996","unstructured":"Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947\u2013954","journal-title":"Clin Chem"},{"key":"4082_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1084\/jem.179.2.405","volume":"179","author":"J Melkko","year":"1994","unstructured":"Melkko J, Hellevick T, Ristelli L, Ristelli J, Smedsrod B (1994) Clearance of NH2 terminal propeptide of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179:405\u2013412","journal-title":"J Exp Med"},{"key":"4082_CR10","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","volume":"44","author":"C Rosenquist","year":"1998","unstructured":"Rosenquist C, Fledelius C, Christgau S, Pedersen B, Bonde M, Qvist P, Christiansen C (1998) Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281\u20132289","journal-title":"Clin Chem"},{"key":"4082_CR11","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1074\/jbc.272.15.9755","volume":"272","author":"C Fledelius","year":"1997","unstructured":"Fledelius C, Johnsen AH, Cloos PA, Bonde M, Qvist P (1997) Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272:9755\u20139763","journal-title":"J Biol Chem"},{"key":"4082_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1515\/cclm-2011-0614","volume":"50","author":"G Lombardi","year":"2012","unstructured":"Lombardi G, Lanteri P, Colombini A, Banfi G (2012) Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling. Clin Chem Lab Med 50:771\u2013789. doi: 10.1515\/cclm-2011-0614","journal-title":"Clin Chem Lab Med"},{"issue":"Suppl 6","key":"4082_CR13","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","volume":"11","author":"R Hannon","year":"2000","unstructured":"Hannon R, Eastell R (2000) Pre-analytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30\u2013S44","journal-title":"Osteoporos Int"},{"key":"4082_CR14","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","volume":"44","author":"S Christgau","year":"1998","unstructured":"Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C (1998) Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290\u20132300","journal-title":"Clin Chem"},{"key":"4082_CR15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","volume":"47","author":"P Garnero","year":"2001","unstructured":"Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694\u2013702","journal-title":"Clin Chem"},{"key":"4082_CR16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","volume":"54","author":"P Garnero","year":"2008","unstructured":"Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188\u2013196","journal-title":"Clin Chem"},{"key":"4082_CR17","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1515\/cclm-2012-0531","volume":"51","author":"A Morovat","year":"2013","unstructured":"Morovat A, Catchpole A, Meurisse A, Carlisi A, Bekaert AC, Rousselle O, Paddon M, James T, Cavalier E (2013) IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin Chem Lab Med 51:2009\u20132018. doi: 10.1515\/cclm-2012-0531","journal-title":"Clin Chem Lab Med"},{"key":"4082_CR18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.clinbiochem.2010.09.019","volume":"43","author":"MK Koivula","year":"2010","unstructured":"Koivula MK, Richardson J, Leino A, Valleala H, Griffiths K, Barnes A et al (2010) Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin Biochem 43:1453\u20131457","journal-title":"Clin Biochem"},{"key":"4082_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","volume":"31","author":"P Qvist","year":"2002","unstructured":"Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57\u201361","journal-title":"Bone"},{"key":"4082_CR20","first-page":"jc2016","volume":"13","author":"J Redmond","year":"2016","unstructured":"Redmond J, Fulford AJ, Jarjou L, Zhou B, Prentice A, Schoenmakers I (2016) Diurnal rhythms of bone turnover markers in three ethnic groups. J Clin Endocrinol Metab 13:jc2016\u2013jc1183","journal-title":"J Clin Endocrinol Metab"},{"key":"4082_CR21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","volume":"30","author":"JA Clowes","year":"2002","unstructured":"Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886\u2013890","journal-title":"Bone"},{"key":"4082_CR22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jsams.2011.09.004","volume":"15","author":"R Weiler","year":"2012","unstructured":"Weiler R, Keen R, Wolman R (2012) Changes in bone turnover markers during the close season in elite football (soccer) players. J Sci Med Sport 15:255\u2013258","journal-title":"J Sci Med Sport"},{"key":"4082_CR23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1373\/clinchem.2010.157289","volume":"57","author":"F Stokes","year":"2011","unstructured":"Stokes F, Ivanov P, Bailey L, Fraser W (2011) The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 57:138\u2013140","journal-title":"Clin Chem"},{"key":"4082_CR24","unstructured":"\u03b2-CrossLaps\/serum (\u03b2-CTX in serum) Immunoassay Cobas package insert (2014\u201309, V 14.0) Roche Diagnostics Corporation, IN, USA"},{"key":"4082_CR25","volume-title":"(total procollagen type I amino-terminal propeptide) immunoassay Cobas package insert (V11.0)","author":"PINP Total","year":"2014","unstructured":"Total PINP (2014) (total procollagen type I amino-terminal propeptide) immunoassay Cobas package insert (V11.0). Roche Diagnostics GmbH, Mannheim"},{"key":"4082_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cccn.2004.07.024","volume":"350","author":"P Qvist","year":"2004","unstructured":"Qvist P, Munk M, Hoyle N, Christiansen C (2004) Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years. Clin Chim Acta 350:167\u2013173","journal-title":"Clin Chim Acta"},{"key":"4082_CR27","first-page":"455","volume":"53","author":"G Lippi","year":"2007","unstructured":"Lippi G, Brocco G, Salvagno GL, Montagnana M, Guidi GC, Schmidt-Gayk H (2007) Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours. Clin Lab 53:455\u2013459","journal-title":"Clin Lab"},{"key":"4082_CR28","first-page":"203","volume":"49","author":"F Huber","year":"2003","unstructured":"Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H (2003) Markers of bone resorption\u2014measurement in serum, plasma or urine? Clin Lab 49:203\u2013207","journal-title":"Clin Lab"},{"key":"4082_CR29","unstructured":"IDS-iSYS (2012) Intact PINP package insert (IS-4000R V01), Immunodiagnostic Systems, Bolden"},{"key":"4082_CR30","unstructured":"IDS-iSYS CTX-I (2013) (CrossLaps) package insert (IS-3000PL V04), Immunodiagnostic Systems, Bolden"},{"key":"4082_CR31","unstructured":"Serum CrossLaps (2010) ELISA package insert (AC-02PL-A), Immunodiagnostic Systems, Bolden"},{"key":"4082_CR32","unstructured":"UniQ PINP RIA, Orion Diagnostica, Espoo, Finland. Cat No. 67034, package insert 35554-13"},{"key":"4082_CR33","unstructured":"NCCLS (now CLSI) (2003) Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; Proposed Guideline. NCCLS document C48-P"},{"key":"4082_CR34","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/clinchem\/45.10.1858","volume":"45","author":"M Wichers","year":"1999","unstructured":"Wichers M, Schmidt E, Bidlingmaier F, Klingm\u00fcller D (1999) Diurnal rhythm of CrossLaps in human serum. Clin Chem 45:1858\u20131860","journal-title":"Clin Chem"},{"key":"4082_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","volume":"26","author":"S Christgau","year":"2000","unstructured":"Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang HD (2000) Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505\u2013511","journal-title":"Bone"},{"key":"4082_CR36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S8756-3282(02)00952-3","volume":"32","author":"AM Ahmad","year":"2003","unstructured":"Ahmad AM, Hopkins MT, Fraser WD, Ooi CG, Durham BH, Vora JP (2003) Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 32:170\u2013179","journal-title":"Bone"},{"key":"4082_CR37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/EJE-10-1108","volume":"164","author":"M Luchavova","year":"2011","unstructured":"Luchavova M, Zikan V, Michalska D, Raska I Jr, Kubena AA, Stepan JJ (2011) The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis. Eur J Endocrinol 164:643\u2013648","journal-title":"Eur J Endocrinol"},{"key":"4082_CR38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/clinchem\/47.8.1410","volume":"47","author":"R Okabe","year":"2001","unstructured":"Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H et al (2001) Clinical evaluation of the Elecsys \u03b2-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 47:1410\u20131414","journal-title":"Clin Chem"},{"key":"4082_CR39","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/clinchem\/47.9.1721","volume":"47","author":"OD Wolthers","year":"2001","unstructured":"Wolthers OD, Heuck C, Heickendorff L (2001) Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. Clin Chem 47:1721\u20131722","journal-title":"Clin Chem"},{"key":"4082_CR40","unstructured":"Tahtela R (2004) Utility of type I collagen-derived markers as reflectors of bone turnover in different clinical situations. University of Helsinki, academic dissertation"},{"key":"4082_CR41","unstructured":"Hoyle N, Wieczorek L (2000) A first technical & clinical review of a new automated serum PINP assay. Int Congress Endo Poster no. 331"},{"key":"4082_CR42","unstructured":"Leary ET, McLaughlin MK, Swezey D, Aggoune T, Carlson TH, Foster AP (2000) Comparison of an automated C-telopeptide assay on the Elecsys 2010 with six serum and urine bone resorption markers in microtiter assay format. JBMR V15 S526, ASBMR poster 2000"},{"key":"4082_CR43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/clinchem\/46.8.1200","volume":"46","author":"A Lomeo","year":"2000","unstructured":"Lomeo A, Bolner A (2000) Stability of several biochemical markers of bone metabolism. Clin Chem 46:1200\u20131202","journal-title":"Clin Chem"},{"key":"4082_CR44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/clinchem\/45.1.47","volume":"45","author":"J Brandt","year":"1999","unstructured":"Brandt J, Krogh TN, Jensen CH, Frederiksen JK, Teisner B (1999) Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 45:47\u201353","journal-title":"Clin Chem"},{"key":"4082_CR45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/gme.0b013e31815f8917","volume":"15","author":"ML Gass","year":"2008","unstructured":"Gass ML, Kagan R, Kohles JD, Martens MG (2008) Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15:667\u2013675","journal-title":"Menopause"},{"key":"4082_CR46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00198-012-1920-2","volume":"24","author":"HP Bhattoa","year":"2013","unstructured":"Bhattoa HP, Nagy E, More C, Kappelmayer J, Balogh A, Kalina E, Antal-Szalmas P (2013) Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study. Osteoporos Int 24:179\u2013186","journal-title":"Osteoporos Int"},{"key":"4082_CR47","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1359\/jbmr.040125","volume":"19","author":"JA Pasco","year":"2004","unstructured":"Pasco JA, Henry MJ, Kotowicz MA, Sanders KM, Seeman E, Pasco JR, Schneider HG, Nicholson GC (2004) Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 19:752\u2013758","journal-title":"J Bone Miner Res"},{"key":"4082_CR48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00223-002-2103-5","volume":"73","author":"P Szulc","year":"2003","unstructured":"Szulc P, Munoz F, Marchand F, Chapuy MC, Delmas PD (2003) Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Calcif Tissue Int 73:520\u2013530","journal-title":"Calcif Tissue Int"},{"key":"4082_CR49","doi-asserted-by":"crossref","unstructured":"Woitge HW, Scheidt-Nave C, Kissling C, Leidig-Bruckner G, Meyer K, Grauer A, Scharla SH, Ziegler R, Seibel MJ (1998) Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab 83:68\u201375","DOI":"10.1210\/jc.83.1.68"},{"key":"4082_CR50","unstructured":"Kitareewan W, Boonhong J, Janchai S, Aksaranugraha S (2011) Effects of the treadmill walking exercise on the biochemical bone markers. J Med Assoc Thail 5(94 Suppl):S10\u2013S16"},{"key":"4082_CR51","doi-asserted-by":"crossref","unstructured":"Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11:281\u2013294","DOI":"10.1007\/s001980070116"},{"key":"4082_CR52","doi-asserted-by":"crossref","unstructured":"Bayer M (2014) Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0-18 years. Osteoporos Int 25:729\u2013736","DOI":"10.1007\/s00198-013-2485-4"},{"key":"4082_CR53","doi-asserted-by":"crossref","unstructured":"Fares JE, Choucair M, Nabulsi M, Salamoun M, Shahine CH, Fuleihan G-H (2003) Effect of gender, puberty, and vitamin D status on biochemical markers of bone remodeling. Bone 33:242\u2013247","DOI":"10.1016\/S8756-3282(03)00160-1"},{"key":"4082_CR54","doi-asserted-by":"crossref","unstructured":"Gracia-Marco L, Vicente-Rodr\u00edguez G, Valtue\u00f1a J, Rey-L\u00f3pez JP, D\u00edaz Mart\u00ednez AE, Mesana MI, Widhalm K, Ruiz JR, Gonz\u00e1lez-Gross M, Castillo MJ, Moreno LA (2010) Bone mass and bone metabolism markers during adolescence: the HELENA Study. Horm Res Paediatr 74:339\u2013350","DOI":"10.1159\/000314965"},{"key":"4082_CR55","doi-asserted-by":"crossref","unstructured":"Szulc P, Kaufman JM, Delmas PD (2007) Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 18:1451\u20131461","DOI":"10.1007\/s00198-007-0407-z"},{"key":"4082_CR56","doi-asserted-by":"crossref","unstructured":"Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD (2001) Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 16:1642\u20131650","DOI":"10.1359\/jbmr.2001.16.9.1642"},{"key":"4082_CR57","doi-asserted-by":"crossref","unstructured":"Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R (2000) The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 15:129\u2013137","DOI":"10.1359\/jbmr.2000.15.1.129"},{"key":"4082_CR58","doi-asserted-by":"crossref","unstructured":"Ritchie LD, Fung EB, Halloran BP, Turnlund JR, Van Loan MD, Cann CE, King JC (1998) A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 67:693\u2013701","DOI":"10.1093\/ajcn\/67.4.693"},{"key":"4082_CR59","doi-asserted-by":"crossref","unstructured":"Zeni SN, Ortela Soler CR, Lazzari A, L\u00f3pez L, Suarez M, Di Gregorio S, Somoza JI, de Portela ML (2003) Interrelationship between bone turnover markers and dietary calcium intake in pregnant women: a longitudinal study. Bone 33:606\u2013613","DOI":"10.1016\/S8756-3282(03)00203-5"},{"key":"4082_CR60","doi-asserted-by":"crossref","unstructured":"Hellmeyer L, Ziller V, Anderer G, Ossendorf A, Schmidt S, Hadji P (2006) Biochemical markers of bone turnover during pregnancy: a longitudinal study. Exp Clin Endocrinol Diabetes 114:506\u2013510","DOI":"10.1055\/s-2006-951627"},{"key":"4082_CR61","doi-asserted-by":"crossref","unstructured":"Carneiro RM, Prebehalla L, Tedesco MB, Sereika SM, Hugo M, Hollis BW, Gundberg CM, Stewart AF, Horwitz MJ (2010) Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover. J Clin Endocrinol Metab 95:1767\u20131776","DOI":"10.1210\/jc.2009-1518"},{"key":"4082_CR62","doi-asserted-by":"crossref","unstructured":"Carneiro RM, Prebehalla L, Tedesco MB, Sereika SM, Gundberg CM, Stewart AF, Horwitz MJ (2013) Evaluation of markers of bone turnover during lactation in African-Americans: a comparison with Caucasian lactation. J Clin Endocrinol Metab 98:523\u2013532","DOI":"10.1210\/jc.2012-2118"},{"key":"4082_CR63","doi-asserted-by":"crossref","unstructured":"Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24:389\u2013397","DOI":"10.1359\/jbmr.080703"},{"key":"4082_CR64","doi-asserted-by":"crossref","unstructured":"Cohen FJ, Eckert S, Mitlak BH (1998) Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women. Calcif Tissue Int 63:277\u2013282","DOI":"10.1007\/s002239900526"},{"key":"4082_CR65","doi-asserted-by":"crossref","unstructured":"Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P (2006) Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. Br J Cancer 95:506\u2013514","DOI":"10.1038\/sj.bjc.6603285"},{"key":"4082_CR66","doi-asserted-by":"publisher","unstructured":"Ferreira A, Alho I, Casimiro S, Costa L (2015) Bone remodeling markers and bone metastases: from cancer research to clinical implications. Bonekey Rep 4:668. doi: 10.1038\/bonekey.2015.35","DOI":"10.1038\/bonekey.2015.35"},{"key":"4082_CR67","unstructured":"Lumachi F, Santeufemia DA, Del Conte A, Mazza F, Tozzoli R, Chiara GB, Basso SM (2013) Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33:2593\u20132596"},{"key":"4082_CR68","unstructured":"Cloos PA, Lyubimova N, Solberg H, Qvist P, Christiansen C, Byrjalsen I, Christgau S (2004) An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50:279\u2013289"},{"key":"4082_CR69","doi-asserted-by":"crossref","unstructured":"Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439\u2013443","DOI":"10.1007\/s001980050030"},{"key":"4082_CR70","doi-asserted-by":"crossref","unstructured":"Kuchuk NO, Pluijm SM, van Schoor NM, Looman CW, Smit JH, Lips P (2009) Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab 94:1244\u20131250","DOI":"10.1210\/jc.2008-1832"},{"key":"4082_CR71","doi-asserted-by":"crossref","unstructured":"Seamans KM, Hill TR, Scully L, Meunier N, Andrillo-Sanchez M, Polito A, Hininger-Favier I, Ciarapica D, Simpson EE, Stewart-Knox BJ, O Connor JM, Coudray C, Cashman KD (2011) Vitamin d status and indices of bone turnover in older European adults. Int J Vitam Nutr Res 81:277\u2013285","DOI":"10.1024\/0300-9831\/a000075"},{"key":"4082_CR72","doi-asserted-by":"crossref","unstructured":"Landew\u00e9 RB, Geusens P, van der Heijde DM, Boers M, van der Linden SJ, Garnero P (2006) Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 65:40\u201344","DOI":"10.1136\/ard.2004.035196"},{"key":"4082_CR73","unstructured":"Chapuy MC, Schott AM, Garnero P, Hans D, Delmas PD, Meunier PJ (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab 81:1129\u20131133"},{"key":"4082_CR74","doi-asserted-by":"crossref","unstructured":"Blumsohn A, Naylor KE, Timm W, Eagleton AC, Hannon RA, Eastell R (2003) Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res 18:1274\u20131281","DOI":"10.1359\/jbmr.2003.18.7.1274"},{"key":"4082_CR75","doi-asserted-by":"crossref","unstructured":"Midtby M, Magnus JH, Joakimsen RM (2001) The Troms\u00f8 Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int 12:835\u2013843","DOI":"10.1007\/s001980170034"},{"key":"4082_CR76","doi-asserted-by":"crossref","unstructured":"Theiler R, St\u00e4helin HB, Kr\u00e4nzlin M, Tyndall A, Bischoff HA (1999) High bone turnover in the elderly. Arch Phys Med Rehabil 80:485\u2013489","DOI":"10.1016\/S0003-9993(99)90186-7"},{"key":"4082_CR77","doi-asserted-by":"crossref","unstructured":"Chen JS, Cameron ID, Cumming RG, Lord SR, March LM, Sambrook PN, Simpson JM, Seibel MJ (2006) Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 21:324\u2013331","DOI":"10.1359\/JBMR.051014"},{"key":"4082_CR78","doi-asserted-by":"crossref","unstructured":"Theiler R, St\u00e4helin HB, Kr\u00e4nzlin M, Somorjai G, Singer-Lindpaintner L, Conzelmann M, Geusens P, Bischoff HA (2000) Influence of physical mobility and season on 25-hydroxyvitamin D-parathyroid hormone interaction and bone remodelling in the elderly. Eur J Endocrinol 143:673\u2013679","DOI":"10.1530\/eje.0.1430673"},{"key":"4082_CR79","doi-asserted-by":"publisher","unstructured":"Lu HK, Zhang Z, Ke YH, He JW, Fu WZ, Zhang CQ, Zhang ZL (2012) High prevalence of vitamin D insufficiency in China: relationship with the levels of parathyroid hormone and markers of bone turnover. PLoS One 7:e47264. doi: 10.1371\/journal.pone. 0047264","DOI":"10.1371\/journal.pone.%200047264"},{"key":"4082_CR80","doi-asserted-by":"crossref","unstructured":"Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM (2006) Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 17:364\u2013372","DOI":"10.1007\/s00198-005-2025-y"},{"key":"4082_CR81","doi-asserted-by":"crossref","unstructured":"Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ (2007) Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 22:1155\u20131164","DOI":"10.1359\/jbmr.070505"},{"key":"4082_CR82","doi-asserted-by":"crossref","unstructured":"Moghaddam A, M\u00fcller U, Roth HJ, Wentzensen A, Gr\u00fctzner PA, Zimmermann G (2011) TRACP 5b and CTX as osteological markers of delayed fracture healing. Injury 42:758\u2013764","DOI":"10.1016\/j.injury.2010.11.017"},{"key":"4082_CR83","doi-asserted-by":"crossref","unstructured":"Ure\u00f1a P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141\u20132156","DOI":"10.1046\/j.1523-1755.1999.00461.x"},{"key":"4082_CR84","doi-asserted-by":"crossref","unstructured":"Tsuchida T, Ishimura E, Miki T, Matsumoto N, Naka H, Jono S, Inaba M, Nishizawa Y (2005) The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int 16:172\u2013179","DOI":"10.1007\/s00198-004-1655-9"},{"key":"4082_CR85","doi-asserted-by":"publisher","unstructured":"Cavalier E, Lukas P, Carlisi A, Gadisseur R, Delanaye P (2013) Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta 425:117\u2013118. doi: 10.1016\/j.cca.2013.07.016","DOI":"10.1016\/j.cca.2013.07.016"},{"key":"4082_CR86","doi-asserted-by":"publisher","unstructured":"Haarhaus M, Fernstr\u00f6m A, Magnusson M, Magnusson P (2009) Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease. Nephrol Dial Transplant 24:3382\u20133389. doi: 10.1093\/ndt\/gfp 300","DOI":"10.1093\/ndt\/gfp%20300"},{"key":"4082_CR87","doi-asserted-by":"crossref","unstructured":"Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16:501\u2013509","DOI":"10.1007\/s00198-004-1712-4"},{"key":"4082_CR88","unstructured":"Reichel H, Roth HJ, Schmidt-Gayk H (2004) Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract 98(4):c112\u2013c118"},{"key":"4082_CR89","doi-asserted-by":"publisher","unstructured":"Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH (2015) Bone turnover markers in Paget\u2019s disease of the bone: a systematic review and meta-analysis. Osteoporos Int 26:1875\u20131891. doi: 10.1007\/s00198-015-3095-0","DOI":"10.1007\/s00198-015-3095-0"},{"key":"4082_CR90","doi-asserted-by":"crossref","unstructured":"Bonnin MR, Moragues C, Nolla JM, Lir\u00f3n FJ, Roig-Escofet D, Navarro MA (1998) Evaluation of circulating type I procollagen propeptides in patients with Paget\u2019s disease of bone. Clin Chem Lab Med 36:53\u201355","DOI":"10.1515\/CCLM.1998.010"},{"key":"4082_CR91","doi-asserted-by":"crossref","unstructured":"Alvarez L, Gua\u00f1abens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Mu\u00f1oz-Gomez J, Ballesta AM (2001) Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget\u2019s disease. Bone 29:447\u2013452","DOI":"10.1016\/S8756-3282(01)00592-0"},{"key":"4082_CR92","doi-asserted-by":"crossref","unstructured":"Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E, Delmas PD (1997) Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget\u2019s disease of bone. J Bone Miner Res 12:1407\u20131415","DOI":"10.1359\/jbmr.1997.12.9.1407"},{"key":"4082_CR93","doi-asserted-by":"publisher","unstructured":"Orford N, Cattigan C, Brennan SL, Kotowicz M, Pasco J, Cooper DJ (2014) The association between critical illness and changes in bone turnover in adults: a systematic review. Osteoporos Int 25:2335\u20132346. doi: 10.1007\/s00198-014-2734-1","DOI":"10.1007\/s00198-014-2734-1"},{"key":"4082_CR94","doi-asserted-by":"crossref","unstructured":"Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R (2003) Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 88:4623\u20134632","DOI":"10.1210\/jc.2003-030358"},{"key":"4082_CR95","doi-asserted-by":"crossref","unstructured":"Ebeling PR, Peterson JM, Riggs BL (1992) Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 7:1243\u20131250","DOI":"10.1002\/jbmr.5650071118"},{"key":"4082_CR96","doi-asserted-by":"crossref","unstructured":"Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub JJ, Kraenzlin M (2004) Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 15:209\u2013216","DOI":"10.1007\/s00198-003-1527-8"},{"key":"4082_CR97","doi-asserted-by":"crossref","unstructured":"Minisola S, Dionisi S, Pacitti MT, Paglia F, Carnevale V, Scillitani A, Mazzaferro S, De GS, Pepe J, Derasmo E, Romagnoli E (2002) Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 13:171\u2013175","DOI":"10.1007\/s001980200009"},{"key":"4082_CR98","doi-asserted-by":"crossref","unstructured":"Wis\u0142owska M, Jakubicz D, Stepie\u0144 K, Cicha M (2009) Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 29:1403\u20131409","DOI":"10.1007\/s00296-009-0867-x"},{"key":"4082_CR99","doi-asserted-by":"crossref","unstructured":"Garnero P, Jouvenne P, Buchs N, Delmas PD, Miossec P (1999) Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone 24:381\u2013385","DOI":"10.1016\/S8756-3282(98)00193-8"},{"key":"4082_CR100","doi-asserted-by":"crossref","unstructured":"Lund T, Abildgaard N, Andersen TL, Delaisse JM, Plesner T (2010) Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol 84:412\u2013420","DOI":"10.1111\/j.1600-0609.2010.01417.x"},{"key":"4082_CR101","doi-asserted-by":"crossref","unstructured":"Kowalska M, Druzd-Sitek A, Fuksiewicz M, Kotowicz B, Chechlinska M, Syczewska M, Walewski J, Kaminska J (2010) Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma. Clin Biochem 43:604\u2013608","DOI":"10.1016\/j.clinbiochem.2009.12.018"},{"key":"4082_CR102","doi-asserted-by":"crossref","unstructured":"Szappanos A, Toke J, Lippai D, Pat\u00f3cs A, Igaz P, Sz\u00fccs N, F\u00fcto L, Gl\u00e1z E, R\u00e1cz K, T\u00f3th M (2010) Bone turnover in patients with endogenous Cushing\u2019s syndrome before and after successful treatment. Osteoporos Int 21:637\u2013645","DOI":"10.1007\/s00198-009-0978-y"},{"key":"4082_CR103","unstructured":"Chiodini I, Carnevale V, Torlontano M, Fusilli S, Guglielmi G, PileriM, Modoni S, DiGiorgio A, LiuzziA, Minisola S, Cammisa M, Trischitta V, Scillitani A (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 83:1863\u20131867"},{"key":"4082_CR104","doi-asserted-by":"publisher","unstructured":"Karatzoglou I, Yavropoulou MP, Pikilidou M, Germanidis G, Akriviadis E, Papazisi A, Daniilidis M, Zebekakis P, Yovos JG (2014) Postprandial response of bone turnover markers in patients with Crohn\u2019s disease. World J Gastroenterol 20:9534\u20139540. doi: 10.3748\/wjg.v20.i28.9534","DOI":"10.3748\/wjg.v20.i28.9534"},{"key":"4082_CR105","doi-asserted-by":"crossref","unstructured":"Gilman J, Shanahan F, Cashman KD (2006) Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther 23:1007\u20131016","DOI":"10.1111\/j.1365-2036.2006.02835.x"},{"key":"4082_CR106","doi-asserted-by":"publisher","unstructured":"Veerappan SG, Healy M, Walsh BJ, O\u2019Morain CA, Daly JS, Ryan BM (2015) Adalimumab therapy has a beneficial effect on bone metabolism in patients with Crohn\u2019s disease. Dig Dis Sci 60:2119\u20132129. doi: 10.1007\/s10620-015-3606-z","DOI":"10.1007\/s10620-015-3606-z"},{"key":"4082_CR107","doi-asserted-by":"crossref","unstructured":"Gua\u00f1abens N, Par\u00e9s A, Alvarez L, Mart\u00ednez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rod\u00e9s J (1998) Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 13:731\u2013738","DOI":"10.1359\/jbmr.1998.13.4.731"},{"key":"4082_CR108","doi-asserted-by":"crossref","unstructured":"F\u00e1brega E, Orive A, Garc\u00eda-Suarez C, Garc\u00eda-Unzueta M, Antonio Amado J, Pons-Romero F (2005) Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int 25:305\u2013310","DOI":"10.1111\/j.1478-3231.2005.01073.x"},{"key":"4082_CR109","doi-asserted-by":"crossref","unstructured":"Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P (2003) High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 38:395\u2013400","DOI":"10.1016\/S0168-8278(02)00435-X"},{"key":"4082_CR110","doi-asserted-by":"crossref","unstructured":"Schytte S, Hansen M, M\u00f8ller S, Junker P, Henriksen JH, Hillings\u00f8 J, Teisner B (1999) Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Scand J Clin Lab Invest 59:627\u2013633","DOI":"10.1080\/00365519950185120"},{"key":"4082_CR111","unstructured":"Haskelberg H, Carr A, Emery S (2011) Bone turnover markers in HIV disease. AIDS Rev 13:240\u2013250"},{"key":"4082_CR112","doi-asserted-by":"crossref","unstructured":"Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators (2004) Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20:2031\u20132041","DOI":"10.1185\/030079904X16768"},{"key":"4082_CR113","doi-asserted-by":"crossref","unstructured":"Binkley N, Silverman SL, Simonelli C, Santiago N, Kohles JD, Dasic G, Sunyecz JA (2009) Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. Osteoporos Int 20:1595\u20131601","DOI":"10.1007\/s00198-008-0827-4"},{"key":"4082_CR114","doi-asserted-by":"crossref","unstructured":"Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537","DOI":"10.1002\/jbmr.251"},{"key":"4082_CR115","doi-asserted-by":"crossref","unstructured":"Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49:1351\u20131356","DOI":"10.1016\/j.bone.2011.09.041"},{"key":"4082_CR116","doi-asserted-by":"crossref","unstructured":"Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, Scott BB, Panebianco D, Ding Y, Gottesdiener K, Wagner JA (2013) Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics\u2014results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 75:1240\u20131254","DOI":"10.1111\/j.1365-2125.2012.04471.x"},{"key":"4082_CR117","doi-asserted-by":"crossref","unstructured":"Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y (2004) Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 22:127\u2013131","DOI":"10.1007\/s00774-003-0460-4"},{"key":"4082_CR118","doi-asserted-by":"crossref","unstructured":"Downs RW Jr, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper K (2010) Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. Osteoporos Int 21:1215\u20131226","DOI":"10.1007\/s00198-009-1060-5"},{"key":"4082_CR119","doi-asserted-by":"crossref","unstructured":"Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36\u201342","DOI":"10.1016\/j.bone.2007.09.001"},{"key":"4082_CR120","doi-asserted-by":"crossref","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","DOI":"10.1002\/art.21918"},{"key":"4082_CR121","doi-asserted-by":"crossref","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","DOI":"10.1136\/ard.2005.044958"},{"key":"4082_CR122","doi-asserted-by":"crossref","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","DOI":"10.1056\/NEJMoa067312"},{"key":"4082_CR123","doi-asserted-by":"crossref","unstructured":"Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S (2014) Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res 29:458\u2013466","DOI":"10.1002\/jbmr.2047"},{"key":"4082_CR124","doi-asserted-by":"crossref","unstructured":"Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937\u2013947","DOI":"10.1359\/jbmr.091035"},{"key":"4082_CR125","unstructured":"Prestwood KM, Kenny AM, Unson C, Kulldorff M (2000) The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 85:4462\u20134469"},{"key":"4082_CR126","doi-asserted-by":"crossref","unstructured":"Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344\u2013351","DOI":"10.1016\/j.bone.2003.10.004"},{"key":"4082_CR127","doi-asserted-by":"crossref","unstructured":"Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S (2009) Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clin Ther 31:751\u2013761","DOI":"10.1016\/j.clinthera.2009.04.018"},{"key":"4082_CR128","doi-asserted-by":"crossref","unstructured":"Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, M\u00f6ricke R, Ziller V (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int 23:625\u2013633","DOI":"10.1007\/s00198-011-1583-4"},{"key":"4082_CR129","doi-asserted-by":"crossref","unstructured":"Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370\u20131375","DOI":"10.1210\/jc.2005-1712"},{"key":"4082_CR130","doi-asserted-by":"publisher","unstructured":"Krege JH, Lane NE, Harris JM, Miller PD (2014) PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 25:2159\u20132171. doi: 10.1007\/s00198-014-2646-0","DOI":"10.1007\/s00198-014-2646-0"},{"key":"4082_CR131","doi-asserted-by":"publisher","unstructured":"Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Alm\u00e5s B, Jorde R (2012) The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass\u2014a randomized controlled 1-year trial. Osteoporos Int 23:201\u2013211. doi: 10.1007\/s00198-011-1752-5","DOI":"10.1007\/s00198-011-1752-5"},{"key":"4082_CR132","doi-asserted-by":"publisher","unstructured":"Kruger MC, Ha PC, Todd JM, Kuhn-Sherlock B, Schollum LM, Ma J, Qin G, Lau E (2012) High-calcium, vitamin D fortified milk is effective in improving bone turnover markers and vitamin D status in healthy postmenopausal Chinese women. Eur J Clin Nutr 66:856\u2013861. doi: 10.1038\/ejcn.2012.54","DOI":"10.1038\/ejcn.2012.54"},{"key":"4082_CR133","doi-asserted-by":"publisher","unstructured":"Aloia J, Bojadzievski T, Yusupov E, Shahzad G, Pollack S, Mikhail M, Yeh J (2010) The relative influence of calcium intake and vitamin D status on serum parathyroid hormone and bone turnover biomarkers in a double-blind, placebo-controlled parallel group, longitudinal factorial design. J Clin Endocrinol Metab 95:3216\u20133224. doi: 10.1210\/jc.2009-1294","DOI":"10.1210\/jc.2009-1294"},{"key":"4082_CR134","doi-asserted-by":"publisher","unstructured":"Zhu K, Bruce D, Austin N, Devine A, Ebeling PR, Prince RL (2008) Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res 23:1343\u20131348. doi: 10.1359\/jbmr.080327","DOI":"10.1359\/jbmr.080327"},{"key":"4082_CR135","doi-asserted-by":"crossref","unstructured":"Albertazzi P, Steel SA, Howarth EM, Purdie DW (2004) Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial. Climacteric 7:33\u201340","DOI":"10.1080\/13697130310001651454"},{"key":"4082_CR136","doi-asserted-by":"crossref","unstructured":"Kauh E, Mixson L, Malice MP, Mesens S, Ramael S, Burke J, Reynders T, Van Dyck K, Beals C, Rosenberg E, Ruddy M (2012) Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals. Eur J Endocrinol 166:459\u2013467","DOI":"10.1530\/EJE-11-0751"},{"key":"4082_CR137","doi-asserted-by":"crossref","unstructured":"Ton FJ, Gunawardene SC, Lee H, Neer RM (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464\u2013470","DOI":"10.1359\/JBMR.041125"},{"key":"4082_CR138","doi-asserted-by":"crossref","unstructured":"Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89:4923\u20134928","DOI":"10.1210\/jc.2004-0164"},{"key":"4082_CR139","doi-asserted-by":"crossref","unstructured":"Gifre L, Ruiz-Gasp\u00e0 S, Monegal A, Nomdedeu B, Filella X, Gua\u00f1abens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57:272\u2013276","DOI":"10.1136\/annrheumdis-2013-eular.918"},{"key":"4082_CR140","doi-asserted-by":"crossref","unstructured":"Anderson WJ, McFarlane LC, Lipworth BJ (2012) Prospective follow-up of novel markers of bone turnover in persistent asthmatics exposed to low and high doses of inhaled ciclesonide over 12 months. J Clin Endocrinol Metab 97:1929\u20131936","DOI":"10.1210\/jc.2011-3410"},{"key":"4082_CR141","doi-asserted-by":"publisher","unstructured":"Coates LC, FitzGerald O, Helliwell PS, Paul C (2016) Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. doi: 10.1016\/j.semarthrit.2016.05.012 online","DOI":"10.1016\/j.semarthrit.2016.05.012%20online"},{"key":"4082_CR142","doi-asserted-by":"crossref","unstructured":"Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353\u2013357","DOI":"10.1136\/ard.2007.076604"},{"key":"4082_CR143","doi-asserted-by":"publisher","unstructured":"Garnero P, Thompson E, Woodworth T, Smolen JS (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62:33\u201343. doi: 10.1002\/art.25053","DOI":"10.1002\/art.25053"},{"key":"4082_CR144","doi-asserted-by":"publisher","unstructured":"Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, Bay-Jensen AC, Platt A (2012) IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 42:131\u2013139. doi: 10.1016\/j.semarthrit.2012.01.004","DOI":"10.1016\/j.semarthrit.2012.01.004"},{"key":"4082_CR145","doi-asserted-by":"crossref","unstructured":"de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz A, Chen E, Rosenberg E, Reitz RE (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222\u20131230","DOI":"10.1016\/j.bone.2007.01.008"},{"key":"4082_CR146","doi-asserted-by":"crossref","unstructured":"Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, Barlow WE (2001) Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab 86:179\u2013185","DOI":"10.1210\/jc.86.1.179"},{"key":"4082_CR147","doi-asserted-by":"publisher","unstructured":"Walsh JS, Eastell R, Peel NF (2010) Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density. Fertil Steril 93:697\u2013701. doi: 10.1016\/j.fertnstert.2008.10.004","DOI":"10.1016\/j.fertnstert.2008.10.004"},{"key":"4082_CR148","doi-asserted-by":"crossref","unstructured":"Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, FranciMB, Lucani B, Francini G, Nuti R (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40:205\u2013210","DOI":"10.1016\/j.bone.2006.06.027"},{"key":"4082_CR149","doi-asserted-by":"crossref","unstructured":"Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21:1215\u20131223","DOI":"10.1359\/jbmr.060508"},{"key":"4082_CR150","doi-asserted-by":"crossref","unstructured":"McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM (2010) A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 119:643\u2013651","DOI":"10.1007\/s10549-009-0646-0"},{"key":"4082_CR151","doi-asserted-by":"crossref","unstructured":"Fitzpatrick LA (2004) Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5:S3\u2013S15","DOI":"10.1016\/j.yebeh.2003.11.026"},{"key":"4082_CR152","doi-asserted-by":"crossref","unstructured":"Lyngstad-Brechan MA, Taub\u00f8ll E, Nakken KO, Gjerstad L, Godang K, Jemtland R, Bollerslev J (2008) Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest 68:759\u2013766","DOI":"10.1080\/00365510802233442"},{"key":"4082_CR153","doi-asserted-by":"crossref","unstructured":"Verrotti A, Greco R, Morgese G, Chiarelli F (2000) Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47:385\u2013388","DOI":"10.1002\/1531-8249(200003)47:3<385::AID-ANA18>3.0.CO;2-W"},{"key":"4082_CR154","doi-asserted-by":"crossref","unstructured":"Heo K, Rhee Y, Lee HW, Lee SA, Shin DJ, Kim WJ, Song HK, Song K, Lee BI (2011) The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 52:1884\u20131889","DOI":"10.1111\/j.1528-1167.2011.03131.x"},{"key":"4082_CR155","doi-asserted-by":"crossref","unstructured":"Koo DL, Hwang KJ, Han SW, Kim JY, Joo EY, Shin WC, Lee HW, Seo DW, Hong SB (2014 Mar) Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 108(3):442\u2013447","DOI":"10.1016\/j.eplepsyres.2013.09.009"},{"key":"4082_CR156","doi-asserted-by":"crossref","unstructured":"Kulak CA, Borba VZ, Silvado CE, Ld P, Seibel MJ, Bilezikian JP, Boguszewski CL (2007) Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy. Arq Bras Endocrinol Metabol 51:466\u2013471","DOI":"10.1590\/S0004-27302007000300016"},{"key":"4082_CR157","doi-asserted-by":"crossref","unstructured":"Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106\u20131118","DOI":"10.1056\/NEJMra041001"},{"key":"4082_CR158","doi-asserted-by":"crossref","unstructured":"Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR (2007) The peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women : a randomized, controlled trial. J Clin Endocrinol Metab 92:1305\u20131310","DOI":"10.1210\/jc.2006-2646"},{"key":"4082_CR159","doi-asserted-by":"crossref","unstructured":"Ross AC, Hileman CO, Brown TT, Fedarko N, Storer N, Labbato D, McComsey GA (2012) Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials 13:212\u2013221","DOI":"10.1310\/hct1304-212"},{"key":"4082_CR160","doi-asserted-by":"crossref","unstructured":"Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE (2010) Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 95:134\u2013142","DOI":"10.1210\/jc.2009-0572"},{"key":"4082_CR161","doi-asserted-by":"crossref","unstructured":"Gruntmanis U, Fordan S, Ghayee HK, Abdullah SM, See R, Ayers CR, McGuire DK (2010) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 86:343\u2013349","DOI":"10.1007\/s00223-010-9352-5"},{"key":"4082_CR162","doi-asserted-by":"crossref","unstructured":"van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE (2012) Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 166:711\u2013716","DOI":"10.1530\/EJE-11-1061"},{"key":"4082_CR163","doi-asserted-by":"crossref","unstructured":"Okazaki R,MiuraM, ToriumiM, TaguchiM, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi Y (1999) Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795\u2013801","DOI":"10.1507\/endocrj.46.795"},{"key":"4082_CR164","doi-asserted-by":"crossref","unstructured":"Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD (2000) Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 109:362\u2013370","DOI":"10.1016\/S0002-9343(00)00510-6"},{"key":"4082_CR165","doi-asserted-by":"crossref","unstructured":"Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18:479\u2013486","DOI":"10.1007\/s00198-006-0259-y"},{"key":"4082_CR166","doi-asserted-by":"publisher","unstructured":"Olmos JM, Hern\u00e1ndez JL, Mart\u00ednez J, Castillo J, Valero C, P\u00e9rez Pajares I, Nan D, Gonz\u00e1lez-Mac\u00edas J (2010) Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment. Maturitas 65:396\u2013402. doi: 10.1016\/j.maturitas.2010.01.007","DOI":"10.1016\/j.maturitas.2010.01.007"},{"key":"4082_CR167","unstructured":"Knapen MHJ, Hellemons-Boode BSP, Langenberg-Ledeboer M, Knottnerus JA, Hamulyak K, Price PA, Vermeer C (2000) Effect of oral anticoagulant treatment on markers for calcium and bone metabolism. Haemostasis 30:290\u2013297"},{"key":"4082_CR168","doi-asserted-by":"crossref","unstructured":"Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall D (2012) National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporosis Int 23:2425\u20132433","DOI":"10.1007\/s00198-012-2049-z"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4082-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:19:30Z","timestamp":1750360770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4082-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":168,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["4082"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4082-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,19]]}}}